Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer

Estramustine phosphate is generally used as a second-line treatment in patients with advanced prostate cancer. The bone metastases due to the cancer are often treated simultaneously with clodronate in order to relieve the bone pain. Therefore, the interaction of clodronate (800 mg orally four times...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacology & toxicology 1996-09, Vol.79 (3), p.157
Hauptverfasser:	Kylmälä, T, Castrén-Kortekangas, P, Seppänen, J, Ylitalo, P, Tammela, T L
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Aged, 80 and over Analgesics, Non-Narcotic - administration & dosage Analgesics, Non-Narcotic - pharmacokinetics Analgesics, Non-Narcotic - therapeutic use Analysis of Variance Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - pharmacokinetics Antineoplastic Agents, Hormonal - therapeutic use Biological Availability Bone Neoplasms - drug therapy Bone Neoplasms - secondary Carcinoma - drug therapy Clodronic Acid - administration & dosage Clodronic Acid - pharmacokinetics Clodronic Acid - therapeutic use Clodronic Acid - urine Drug Synergism Drug Therapy, Combination Estramustine - administration & dosage Estramustine - pharmacokinetics Estramustine - therapeutic use Estramustine - urine Gas Chromatography-Mass Spectrometry Humans Male Middle Aged Pain - drug therapy Prostatic Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!